Biotech Values

[DewDiligence]

IDIX 2010 Possible/Probable News Flow

[Updated for2/8/10 BioCEO webcast. The only change is
that final data from the first two cohorts of the phase-2a
IDX184 study will be presented at EASL. (The first cohort,
50mg qD, has been completed without any SAE’s.)]


HCV

Apr 2010 at EASL: Report data from 50mg qD and 100mg qD/BID cohorts of phase-2a trial of IDX184 nucleotide polymerase inhibitor. (Interim data from the 50mg qD cohort were reported on 1/11/10.)

Apr 2010 at EASL: Report additional phase-1 data for IDX375 non-nucleoside polymerase inhibitor. (Interim data were reported on 1/11/10.)

2010 (timing uncertain): Ink IDX184 partnership.

Mid 2010: Start phase-1/2 PoC study for IDX375.

Mid 2010: Start phase-1/2 PoC study for IDX320.

Nov 2010 at AASLD: Present complete phase-2a data for IDX184.

2H10: Select lead compound for NS5A program. Start phase-1 in 1H11.


HIV

Mar 2010: GSK* completes IDX899 PK/food study testing multiple formulations at 100mg qD (#msg-44790049).

2Q10: Start phase-2b trials of IDX899 in treatment-naïve and treatment-experienced settings using the preferred 100mg formulation from the PK/food study.

*GSK is the operator of ViiV Healthcare, the joint venture with PFE that is the licensee of IDX899 (#msg-43254006).